Last reviewed · How we verify
NCT06199349
Safety Study of GMDTC Injection in Participants With Excessive Cadmium
Phase 1 trial testing GMDTC for injection in Cadmium Exceeds the Standard in 30 participants. Completed in 5 December 2024.
21 October 2024
Quick facts
| Lead sponsor | Jianersheng (Zhuhai) Pharmaceutical Technology Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | other |
| Enrollment | 30 |
| Start date | 8 January 2024 |
| Primary completion | 21 October 2024 |
| Estimated completion | 5 December 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- GMDTC for injection — full drug profile →
- Normal saline
Conditions studied
- Cadmium Exceeds the Standard — all drugs for Cadmium Exceeds the Standard →
Sponsor
Jianersheng (Zhuhai) Pharmaceutical Technology Co., Ltd.
Who can join
18 and older, any sex, with Cadmium Exceeds the Standard. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial is a randomized, double-blind, single-center, single-dose escalating Phase I clinical trial designed to evaluate the safety, tolerability, and pharmacokinetic characteristics of GMDTC for injection after repeated administration in people with excessive cadmium levels.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06199349
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of GMDTC for injection
Trials testing the same drug.
- NCT07057414 — The Safety and Efficacy of GMDTC for Injection in Subjects With Elevated Cadmium Levels · Phase 2 · recruiting
- NCT05908383 — Safety Study of GMDTC Injection in Healthy Participants · Phase 1 · completed
Other recruiting trials for Cadmium Exceeds the Standard
Currently open trials in the same condition.
- NCT07057414 — The Safety and Efficacy of GMDTC for Injection in Subjects With Elevated Cadmium Levels · Phase 2 · recruiting
- NCT06572566 — Study on Neuropsychiatric Behavior in Cadmium-exposed People · recruiting
Other Jianersheng (Zhuhai) Pharmaceutical Technology Co., Ltd. trials
Trials by the same sponsor.
- NCT06572566 — Study on Neuropsychiatric Behavior in Cadmium-exposed People · recruiting
- NCT05908383 — Safety Study of GMDTC Injection in Healthy Participants · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06199349 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jianersheng (Zhuhai) Pharmaceutical Technology Co., Ltd.
- Last refreshed: 20 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06199349.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing